Pharmacologic prevention of skeletal-related events in cancer patients

Orthopedics

Volumn 33, Issue 8, 2010, Pages

  Bottiglieri, Sal ^a   Adams, Val ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DENOSUMAB; HEMOGLOBIN; PAMIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTHRALGIA; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CELL; CANCER PATIENT; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DRUG APPROVAL; DRUG EFFICACY; ELECTROLYTE BLOOD LEVEL; FLU LIKE SYNDROME; HEMOGLOBIN DETERMINATION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INCIDENCE; JAW OSTEONECROSIS; KIDNEY FUNCTION; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEPHROTOXICITY; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PATIENT MONITORING; PRACTICE GUIDELINE; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKELETON; TREATMENT OUTCOME; VOMITING; BONE TUMOR; METASTASIS; PROGNOSIS;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; FRACTURES, SPONTANEOUS; HUMANS; INCIDENCE; NEOPLASM METASTASIS; PROGNOSIS;

EID: 77955643172     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20100625-20     Document Type: Review

References (20)

1. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110(8):1860-1867. (Pubitemid 47557312)
2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 Pt 2):6243s-6249s.
3. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009; 101(12):878-887.
4. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351(18):1860-1873.
5. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.
6. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with different types of cancer. Acta Oncol. 2009; 48(1):105-115.
7. Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80(8 Suppl):1588-1594.
8. Michaelson MD, Rosenthal DI, Smith MR. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol. 2004; 22(20):4233-4234. (Pubitemid 41185198)
9. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96(11):879-882. (Pubitemid 38807610)
10. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003; 21 (23):4277-4284. (Pubitemid 46621802)
11. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335(24):1785-1791.
12. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7(5):377-387. (Pubitemid 33759002)
13. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004; 100(1):36-43. (Pubitemid 37553537)
14. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer. 2003; 98(8):1735-1744. (Pubitemid 37238631)
15. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003; 21(21):4042-4057.
16. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007; 25(17):2464-2472.
17. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006; 134(6):620-623. (Pubitemid 44253605)
18. Denosumab demonstrated superiority over Zometa in pivotal phase 3 head-to-head trial in prostate cancer patients with bone metastasis. Amgen Web site. http://www.amgen.com/media/media-pr-detail.jsp?releaseID=1385163. Published February 8, 2010. Accessed February 8, 2010.
19. Stopeck A, Body JJ, Fujiwara Y. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastasis: results of a randomized phase 3 study. Eur J Can Suppl. 2009;7(3):2-3. <
20. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009; 27(10):1564-1571.